Home Tags Belantamab mafodotin

Tag: belantamab mafodotin

U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple...

The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients with relapsed or refractory multiple...

CHMP Adopts Positive Opinion for Belantamab Mafodotin, Recommending Approval for the...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...

Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...

The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
Featured Image: Better times - ASCO | McCormick Place. Courtesy: © 2017 Fotolia. Used with permission.

ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into new therapies is needed as...

Belantamab Mafodotin Receives Priority Review for Relapsed or Refractory Multiple Myeloma

The United States Food and Drug Administration (FDA) has granted a priority review of a Biologics License Application (BLA) for belantamab mafodotin (GSK2857916), a...

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate or...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, and GlaxoSmothKline have entered into...

EHA 2019: Belantamab Mafodotin in Patients with R/R Multple Myeloma

New, updated, data on belantamab mafodotin, also known as GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), were presented at the 24th...